.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,358,718

« Back to Dashboard

Details for Patent: 5,358,718

Title: Tablet containing mesna as active substance and method of making same
Abstract:A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain: 0.01-1 parts by weight of a binding agent 0.03-0.4 parts by weight of a disintegrant 0.01-0.2 parts by weight of a lubricant and 0.1-1 parts by weight of a filling agent as well as, in the case of an effervescent tablet, an additional 0.05-30 parts by weight of a conventional physiologically acceptable effervescent mixture.
Inventor(s): Sauerbier; Dieter (Werter, DE), Engel; Jurgen (Alzenau, DE), Milsmann; Eckhard (Bielefeld, DE)
Assignee: Degussa (Hanau, DE)
Filing Date:Jul 26, 1993
Application Number:08/096,422
Claims:1. A tablet comprising, as active ingredient, mesna in combination with, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate.

0.05-30 parts by weight, for each part by weight of mesna, of a conventional physiologically acceptable effervescent mixture.

2. An effervescent tablet as set forth in claim 1 containing, in addition, at least one member of the group consisting of conventional flavoring, sweetening and aromatizing substances.

3. An effervescent tablet as set forth in claim 1 which contains 10-80 percent by weight of mesna.

4. A tablet as set forth in claim 1 which is coated with a pharmaceutically-acceptable coating.

5. A process for the manufacture of a stable oral dosage form of mesna which contains, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate

0.05-30 parts by weight of a physiologically acceptable effervescent mixture

said process including the step of granulating the mesna with at least one member of the group consisting of C.sub.1 -C.sub.4 -alcohols, acetone and mixtures of these organic agents with water, together with at least a portion of said filling agent and at least a portion of said binding agent and converting the resulting granulate into a stable oral dosage form of mesna.

6. A process as set forth in claim 5 including the step of drying the granulate thus formed.

7. A process as set forth in claim 5 including the step of combining the granulate thus formed with a lubricant.

8. A process as set forth in claim 6 or claim 7 including the step of pressing the granulate into tablets.

9. A process as set forth in claim 8 including the step of applying a pharmaceutically-acceptable coating to the tablets.

10. A process for the manufacture of a stable oral dosage form of mesna in which the stable oral dosage form of mesna consists essentially of, for each part by weight of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite 0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate

0.05-30 parts by weight of a physiologically acceptable effervescent mixture

said process comprising granulating mesna with at least one member of the group consisting of C.sub.1 -C.sub.4 -alcohols, acetone and mixtures of these organic agents with water, together with at least a portion of the filling agent to be included in said stable oral dosage form and at least a portion of the binding agent to be included in said stable oral dosage form and combining the resulting granulate with any part of said binding agent and any part of said filling agent not used during the granulation and with said lubricant, said disintegrant and said effervescent mixture to form said stable oral dosage form of mesna.

11. A process as set forth in claim 10 including the step of drying the granulate thus formed.

12. A process of making a tablet containing mesna which consists essentially of, for each part of mesna:

0.01-1 parts by weight of a binding agent selected from the group consisting of polyvinylpyrrolidone, gelatin and microcrystalline cellulose

0.03-0.4 parts by weight of a disintegrant selected from the group consisting of starch, crosslinked polyvinylpyrrolidone and bentonite

0.01-0.2 parts by weight of a lubricant selected from the group consisting of stearates, talcum and polyglycols

0.1-1 parts by weight of a filling agent selected from the group consisting of starch, cellulose, lactose, fructose, saccharose, sorbitol, mannitol, calcium phosphate and calcium hydrogen phosphate

0.05-30 parts by weight of a physiologically acceptable effervescent mixture

said process comprising granulating mesna with at least one member of the group consisting of C.sub.1 -C.sub.4 -alcohols, acetone and mixtures of these organic agents with water, together with at least a portion of the filling agent to be included in said tablet and at least a portion of binding agent to be included in said tablet, combining the resulting granulate with any part of said binding agent and any part of said filling agent not used during the granulation and with said lubricant, said disintegrant and said effervescent mixture, and pressing the resulting mixture to form a tablet.

13. A method as set forth in claim 12 including the step of applying a pharmaceutically-acceptable coating to said tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc